TEVA insider sale notice: Form 144 lists RSU/PSU vesting

Teva Pharmaceutical Industries disclosed a Form 144 notice reporting intended sales of ordinary shares.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries disclosed a Form 144 notice reporting intended sales of ordinary shares. The filing lists restricted and performance share unit awards vesting on 03/03/2026 with quantities of 24,900, 110,668, and 30,810 shares tied to compensation awards. The broker listed is Citigroup Global Markets.

Insights

Insider Transactions Compliance Analyst

Form 144 notifies the market of planned resale by an affiliate; timing and exact sale mechanics are not specified.

The filing lists three compensation awards vesting on 03/03/2026 totaling named share amounts: 24,900, 110,668, and 30,810. It also names Citigroup Global Markets as the broker.

These entries indicate intended resale under Rule 144; the filing does not state execution timing, proceeds, or whether the shares will be sold immediately after vesting. Subsequent filings or trade reports will show actual transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 report?

The filing reports intended resale of ordinary shares tied to compensation awards. It lists awards vesting on 03/03/2026 totaling 24,900, 110,668, and 30,810 shares and names Citigroup Global Markets as broker.

Do the listed awards mean shares have already been sold?

No; the Form 144 signals intent to sell under Rule 144. The filing lists vesting on 03/03/2026 but does not state that sales occurred or the sale timing.

Who is the broker handling the potential sales for TEVA?

The broker named in the filing is Citigroup Global Markets, located at 390 Greenwich St., New York. The record in the excerpt associates that broker with the listed ordinary shares.

How many shares are tied to the compensation awards in this filing?

The excerpt shows three award quantities: 24,900 (restricted share units), 110,668 (performance share units), and 30,810 (performance share units), all tied to vesting on 03/03/2026.

Does Form 144 disclose proceeds or sale methods?

The provided excerpt does not disclose sale proceeds or detailed sale methods. It lists award types, vesting 03/03/2026, quantities, and the broker but not execution terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001938678
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Hughes Eric A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	80762	2613450.24	1149812898	03/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2023	RESTRICTED SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			24900	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	PERFORMANCE SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			110668	03/03/2026	COMPENSATION
ORDINARY SHARES	03/03/2023	PERFORMANCE SHARE UNIT AWARD VESTING EM	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			30810	03/03/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED UNDER AN ESTABLISHED 10B51 PLAN ADOPTED NOVEMBER 2025
Date of Notice	03/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)